Related Experiment Video

Updated: May 24, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

Hubing Shi1, Gatien Moriceau, Xiangju Kong

  • 1Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52-121 CHS, 10833 Le Conte Avenue, California 90095-1750, USA.

Nature Communications
|March 8, 2012
PubMed

Insights

Melanoma patients can develop resistance to B-RAF inhibitors through a copy-number gain of (V600E)B-RAF. This genetic change can be overcome by targeting MEK1/2 or combining therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Acquired drug resistance limits the effectiveness of B-RAF inhibitor therapy in melanoma.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of (V600E)B-RAF copy-number gain as a mechanism of acquired B-RAF inhibitor resistance.
  • To explore therapeutic strategies to overcome this resistance.

Main Methods:

  • Analysis of tumor samples from melanoma patients treated with B-RAF inhibitors.
  • In vitro studies using melanoma cell lines to assess the impact of (V600E)B-RAF overexpression and knockdown.
  • Pharmacological inhibition of extracellular signal-regulated kinase (ERK) pathway components.

Main Results:

  • A (V600E)B-RAF copy-number gain was identified in 20% of treated melanoma patients, conferring resistance.
  • (V600E)B-RAF overexpression induced resistance, while knockdown sensitized cells to B-RAF inhibitors.
  • ERK reactivation in (V600E)B-RAF amplification-driven resistance is targetable with MEK1/2 inhibitors (AZD6244/selumetinib) or combination therapy.
  • (V600E)B-RAF amplification-mediated resistance is largely independent of C-RAF, unlike NRAS-mutant resistance.

Conclusions:

  • (V600E)B-RAF copy-number gain is a significant mechanism of acquired resistance to B-RAF inhibitors in melanoma.
  • Targeting the ERK pathway with MEK1/2 inhibitors offers a potential strategy to overcome this specific resistance mechanism.
  • Distinct resistance mechanisms may necessitate tailored therapeutic approaches for melanoma patients.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...